Safety of Ultrasound-Guided Foam Sclerotherapy with Physiological CO2-O2 Gas : Abstract 2/28/2009 Before documented, evidence based, RCT clinical studies were published. Helping physicians, health care providers understand why Morrison Vein Institute uses CO2/O2 Foam for our therapies.
Purpose: Validate the safety profile of large volume ultrasound-guided foam sclerotherapy (UGFS) using Polidocanol and carbon dioxide/oxygen (CO2/O2) gas and compare with safety profiles of foam produced with air and pure CO2.
Method: UGFS followed previous thermal ablation of the great saphenous vein (GSV) in 100 patients. The majority of patients were female (94%) and over 50 years old. Great saphenous veins, small saphenous veins (SSV) and their tributaries were treated in a variety of combinations using 2-48 ml of foam. Response data were captured immediately following and up to 24 hours post interventions. Logistic profile trials were tested.
Result: No physiologically significant changes in vital sign or EKG were observed. When comparing the injection groups, no difference were found in the probabilities of not experiencing leg pain (p=0.615) or itching (p=0.252). The odds of not experiencing dry cough, metallic taste, or chest tightness (combined) was nearly 40 times greater for the CO2/O2 based foam group and 17 times greater for the CO2 based foam group than for the Air Foam group. The odds of not experiencing nausea, dizziness or visual disturbance (combined) was 7.3 times greater for the CO2/O2 based foam group than for the air-based foam group. Studies performed in Morrison Vein Institute, Arizona
Safety, patient comfort and effective vein treatments have been a priority @MorrisonVein for 21 years. We are always researching to improve patient outcomes with the most modern, safe, efficient means available. Come see us, call for a free compression stocking fitting appointment and we will start with a video and conversation about your needs. 480-775-8460 1-866- GRT-LEGS toll free.